nach oben

Erschienen in:

02.07.2019 | Original Article

Ascites from Ovarian Cancer Induces Novel Fucosylated Proteins

verfasst von: Dulce Rosario Alberto-Aguilar, Verónica Ivonne Hernández-Ramírez, Juan Carlos Osorio-Trujillo, Dolores Gallardo-Rincón, Alfredo Toledo-Leyva, Patricia Talamás-Rohana

Erschienen in: Cancer Microenvironment | Ausgabe 2-3/2019

Einloggen, um Zugang zu erhalten

Abstract

Ovarian cancer is considered to be the most lethal type of gynecological cancer. During the advanced stages of ovarian cancer, an accumulation of ascites is observed. Fucosylation has been classified as an abnormal post-translational modification that is present in many diseases, including ovarian cancer. Ovarian cancer cells that are cultured with ascites stimulation change their morphology; concomitantly, the fucosylation process is altered. However, it is not known which fucosylated proteins are modified. The goal of this work was to identify the differentially fucosylated proteins that are expressed by ovarian cancer cell lines that are cultured with ovarian cancer patients’ ascites. Aleuria aurantia lectin was used to detect fucosylation, and some changes were observed, especially in the cell membrane. Affinity chromatography and mass spectrometry (MALDI-TOF) were used to identify 6 fucosylated proteins. Four proteins (Intermediate filament family orphan 1 [IFFO1], PHD finger protein 20-like protein 1 [PHF20L1], immunoglobulin gamma 1 heavy chain variable region partial [IGHV1–2], and Zinc finger protein 224 [ZNF224]) were obtained from cell cultures stimulated with ascites, and the other two proteins (Peregrin [BRPF1] and Dystrobrevin alpha [DTNA]) were obtained under normal culture conditions. The fucosylated state of some of these proteins was further analyzed. The experimental results show that the ascites of ovarian cancer patients modulated the fucosylation process. The PHD finger protein 20-like protein 1, Zinc finger protein 224 and Peregrin proteins colocalize with fucosylation at different levels.

Nur mit Berechtigung zugänglich

GLOBOCAN, 2018. Estimated cancer incidence and prevalence woldwide in 2018. [online] Available at: http://globocan.iarc.fr [Last access: 24^th March 2019]

Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22(2):255–288PubMed

Cvetkovic D (2003) Early events in ovarian oncogenesis. Reprod Biol Endocrinol 1(68):68. https://doi.org/10.1186/1477-7827-1-68 CrossRefPubMedPubMedCentral

Odicino F, Pecorelli S, Zigliani L, Creasman W (2008) History of the FIGO cancer staging system. Int J Gynecol Obstet 101(2):205–210. https://doi.org/10.1016/j.ijgo.2007.11.004 CrossRef

Pasquet M, Golzio M, Mery E, Rafii A, Benabbou N, Mirshahi P, Hennebelle I, Bourin P, Allal B, Teissie J, Mirshahi M, Couderc B (2010) Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer 126(9):2090–2101. https://doi.org/10.1002/ijc.24886 CrossRefPubMed

Lane D, Bachvarov D, Rancourt C, Piche A (2014) Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer 14:288. https://doi.org/10.1186/1471-2407-14-288 CrossRefPubMedPubMedCentral

Shender VO, Pavlyukov MS, Ziganshin RH, Arapidi GP, Kovalchuk SI, Anikanov NA, Altukhov IA, Alexeev DG, Butenko IO, Shavarda AL, Khomyakova EB, Evtushenko E, Ashrafyan LA, Antonova IB, Kuznetcov IN, Gorbachev AY, Shakhparonov MI, Govorun VM (2014) Proteome–metabolome profiling of ovarian Cancer ascites reveals novel components involved in intercellular communication. Mol Cell Proteomics 13(12):3558–3571. https://doi.org/10.1074/mcp.M114.041194 CrossRefPubMedPubMedCentral

Bery A, Leung F, Smith CR, Diamandis EP, Kulasingam V (2014) Deciphering the ovarian cancer ascites fluid peptidome. Clin Proteomics 11(1):13. https://doi.org/10.1186/1559-0275-11-13 CrossRefPubMedPubMedCentral

Pinho S, Reis C (2015) Glycosylation in cancer: mechanism and clinical implications. Nat Rev Cancer 15(9):540–555. https://doi.org/10.1016/j.neo.2018.06.001 CrossRefPubMed

10.

Miyoshi E, Moriwaki K, Nakagawa T (2008) Biological function of fucosylation in cancer biology. J Biochem 143(6):725–729. https://doi.org/10.1093/jb/mvn011 CrossRefPubMed

11.

Shah M, Telang S, Shah P, Patel P (2008a) Tissue and serum α2-3-and α2-6-linkage specific sialylation changes in oral carcinogenesis. Glycoconj J 25(3):279–290. https://doi.org/10.1007/s10719-007-9086-4 CrossRefPubMed

12.

Shah M, Telang S, Raval G, Shah P, Patel PS (2008b) Serum fucosylation changes in oral cancer and oral precancerous conditions. Cancer J 113(2):336–346. https://doi.org/10.1002/cncr.23556 CrossRef

13.

Vajaria B, Patel P (2016) Glycosylation: a halmark of cancer? Glycoconj J 34(2):147–156. https://doi.org/10.1007/s10719-016-9755-2 CrossRefPubMed

14.

Hu Z, Cai M, Deng L, Zhu L, Gao J, Tan M, Liu J, Lin B (2016) The fucosylated CD147 enhances the autophagy in epithelial ovarian cancer cells. Oncotarget 7(50):82921–82932. https://doi.org/10.18632/oncotarget.13289 CrossRefPubMedPubMedCentral

15.

Zhuang H, Hu Z, Tan M, Zhu L, Liu J, Liu D, Yan L, Lin B (2014) Overexpression of Lewis y antigen promotes human epididymis protein 4-mediated invasion and metastasis of ovarian cancer cells. Biochimie 105:91–98. https://doi.org/10.1016/j.biochi.2014.06.022 CrossRefPubMed

16.

Cai M, Jin S, Deng L, Zhu L, Hu Z, Liu D, Liu J, Tan M, Gao J, Wang H, Lin B (2017) Lewis y antigen promotes p27 degradation by regulating ubiquitin-proteasome activity. Oncotarget 8(66):110064–110076. https://doi.org/10.18632/oncotarget.22617 CrossRefPubMedPubMedCentral

17.

Liu J, Zheng M, Qi Y, Wang H, Liu M, Liu Q, Lin B (2018) Lewis(y) antigen-mediated positive feedback loop induces and promotes chemotherapeutic resistance in ovarian cancer. Int J Oncol 53(4):1774–1786. https://doi.org/10.3892/ijo.2018.4496 CrossRefPubMed

18.

Thomson S, Dargan E, Turner GA (1992) Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer. Cancer Lett 66:43–48CrossRef

19.

Garibay-Cerdenares OL, Hernández-Ramírez VI, Osorio-Trujillo JC, Hernández-Ortíz M, Gallardo-Rincón D, Cantú de León D, Encarnación-Guevara S, Villegas-Pineda JC, Talamás-Rohana P (2014) Proteomic identification of fucosylated haptoglobin alpha isoforms in ascitic fluids and its localization in ovarian carcinoma tissues from Mexican patients. J Ovarian Res 7:27. https://doi.org/10.1186/1757-2215-7-27 CrossRefPubMedPubMedCentral

20.

Villegas-Pineda JC, Garibay-Cerdenares OL, Hernández-Ramírez VI, Gallardo-Rincón D, Cantú de León D, Pérez-Montiel-Gómez MD, Talamás-Rohana P (2015) Integrins and haptoglobin: molecules overexpressed in ovarian cancer. Pathol Res Pract 211(12):973–981. https://doi.org/10.1016/j.prp.2015.10.002 CrossRefPubMed

21.

Yarnashita K, Korde N, Endo T, Iwaki Y, Kobata A (1989) Altered glycosylation of serum transferrin of patients with hepatocellular carcinoma. J Biol Chem 264:2415–2423

22.

Aoyagi Y, Isernura M, Yosizawa Z, Suzuki Y, Sekine C, Ono T, Ichida F (1985) Fucosylation of serum o-fetoprotein in patients with primary hepatocellular carcinoma. Biochim Biophs Acta 830:217–223CrossRef

23.

Yamamoto K, Tsujii T, Tarutani O, Osawa T (1984) Structural changes of carbohydrate chains of human thyroglobulin accompanying tranformations of thyroid glands. Eur J Biochem 143:133–144CrossRef

24.

Toledo-Leyva A, Villegas-Pineda JC, Encarnación-Guevara S, Gallardo-Rincón D, Talamás Rohana P (2018) Effect of ovarian cancer ascites on SKOV-3 cells proteome: new proteins associated with aggressive phenotype in epithelial ovarian cancer. Proteome Sci 16:3. https://doi.org/10.1186/s12953-018-0133-9 CrossRefPubMedPubMedCentral

25.

Carduner L, Picot CR, Leroy-Dudal J, Blay L, Kellouche S, Carreiras F (2014) Cell cycle arrest or survival signaling through αv integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids. Exp Cell Res 320(2):329–342. https://doi.org/10.1016/j.yexcr.2013.11.011 CrossRefPubMed

26.

Runyon BA (1994) Care of patients with ascites. N Engl J Med 330:337–342. https://doi.org/10.1056/NEJM199402033300508 CrossRefPubMed

27.

Shen-Gunther J, Mannel RS (2002) Ascites as a predictor of ovarian malignancy. Gynecol Oncol 87(1):77–83CrossRef

28.

Offner FA, Obrist P, Stadlmann S, Feichtinger H, Klingler P, Herold M, Zwierzina H, Hittmair A, Mikuz G, Abendstein B, Zeimet A, Marth C (1995) IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 7(6):542–547CrossRef

29.

Matte I, Lane D, Laplante C, Rancourt C, Piche A (2012) Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res 2(5):566–580PubMedPubMedCentral

30.

Matte I, Lane D, Bachvarov D, Rancourt C, Piche A (2014) Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer 14:288. https://doi.org/10.1186/1471-2407-14-288 CrossRefPubMedPubMedCentral

31.

Matte I, Lane D, Laplante C, Garde-Granger P, Rancourt C, Piche A (2015) Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms. Int J Cancer 137(2):289–298. https://doi.org/10.1002/ijc.29385 CrossRefPubMed

32.

Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432(7015):332–337CrossRef

33.

Wels J, Kaplan RN, Rafii S, Lyden D (2008) Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 22(5):559–574. https://doi.org/10.1101/gad.1636908 CrossRefPubMedPubMedCentral

34.

Villegas-Pineda JC, Toledo-Leyva A, Osorio-Trujillo C, Hernández-Ramírez VI, Talamás-Rohana P (2017) The translational blocking of α5 and α6 integrin subunits affects migration and invasion, and increases sensitivity to carboplatin of SKOV-3 ovarian cancer cell line. Exp Cell Res 351(2):127–134. https://doi.org/10.1016/j.yexcr.2017.01.010 CrossRefPubMed

35.

So KA, Min KJ, Hong JH, Lee JK (2015) Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial–mesenchymal transition. Int J Oncol 47(4):1451–1459. https://doi.org/10.3892/ijo.2015.3122 CrossRefPubMed

36.

Lane D, Matte I, Rancourt C, Piche A (2012) Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis. J Ovarian Res 5(1):34. https://doi.org/10.1186/1757-2215-5-34 CrossRefPubMedPubMedCentral

37.

Reid PE, Brown NJ, Holen I (2009) Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact. Mol Cancer 8:49. https://doi.org/10.1186/1476-4598-8-49 CrossRefPubMedPubMedCentral

38.

Yin J, Zeng F, Wu N, Kang K, Yang Z, Yang H (2015) Interleukin-8 promotes human ovarian cancer cell migration by epithelial-mesenchymal transition induction in vitro. Clin Transl Oncol 17(5):365–370. https://doi.org/10.1007/s12094-014-1240-4 CrossRefPubMed

39.

Lane D1, Matte I, Rancourt C, Piché A (2011) Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 30(11):210. https://doi.org/10.1186/1471-2407-11-210 CrossRef

40.

Giuntoli RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M (2009) Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 29:2875–2884PubMed

41.

Terao N, Takamatsu S, Minehira T, Sobajima T, Nakayama K, Kamada Y, Miyoshi E (2015) Fucosylation is a common glycosylation type in pancreatic cancer stem cell-like phenotypes. World J Gastroenterol 21(13):3876–3887. https://doi.org/10.3748/wjg.v21.i13.3876 CrossRefPubMedPubMedCentral

42.

Syed V, Ulinski G, Mok SC, Ho SM (2002) Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 94:617–629CrossRef

43.

Obata NH, Tamakoshi K, Shibata K, Kikkawa F, Tomoda Y (1997) Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 17:337–342PubMed

44.

Nilsson MB, Langley RR, Fidler IJ (2005) Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 65:10794–10800. https://doi.org/10.1158/0008-5472.CAN-05-0623 CrossRefPubMedPubMedCentral

45.

Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, Meng XY (2012) Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine 59(1):145–155. https://doi.org/10.1016/j.cyto.2012.04.013 CrossRefPubMed

46.

Soon H, Moon A (2010) Epithelial-mesenchymal transition and cell invasion. Toxicol Res 26(4):245–252. https://doi.org/10.5487/TR.2010.26.4.245 CrossRef

47.

Smith PL, Myers JT, Rogers CE, Zhou L, Petryniak B, Becker DJ, Homeister JW, Lowe JB (2002) Conditional control of selectin ligand expression and global fucosylation events in mice with a targeted mutation at the FX locus. J Cell Biol 158:801–815CrossRef

48.

Chao YB, Scovell WM, Yan SB (1994) High mobility group protein, HMG-1, contains insignificant glycosyl modification. Protein Sci 3(12):2452–2454. https://doi.org/10.1002/pro.5560031230 CrossRefPubMedPubMedCentral

49.

Hart GW, Haltiwanger RS, Holt GD, Kelly WG (1989) Glycosylation in the nucleus and cytoplasm. Annu Rev Biochem 58:841–874CrossRef

50.

Feizi T (2000) Carbohydrate-mediated recognition systems in innate immunity. Immunol Rev 173:79–88CrossRef

51.

Marth JD, Grewal PK (2008) Mammalian glycosylation in immunity. Nat Rev Immunol 8:874–887CrossRef

52.

Pickard JM, Maurice CF, Kinnebrew MA, Abt MC, Schenten D, Golovkina TV, Bogatyrev SR, Ismagilov RF, Pamer EG, Turnbaugh PJ, Chervonsky AV (2014) Rapid fucosylation of intestinal epithelium sustains host–commensal symbiosis in sickness. Nature 514:638–641. https://doi.org/10.1038/nature13823 CrossRefPubMedPubMedCentral

53.

Myers J, Huang Y, Wei L, Yan Q, Huang A, Zhou L (2010) Fucose-deficient hematopoietic stem cells have decreased self-renewal and aberrant marrow niche occupancy. Transfusion 50:2660–2669. https://doi.org/10.1111/j.1537-2995.2010.02745.x CrossRefPubMedPubMedCentral

54.

Soochi K, Boyun K, Sang Song Y (2016) Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci 107(9):1173–1178. https://doi.org/10.1111/cas.12987 CrossRef

55.

Larsen RD, Ernst LK, Nair RP, Lowe JB (1990) Molecular cloning, sequence, and expression of a human GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase cDNA that can form the H blood group antigen. Proc Natl Acad Sci U S A 87:6674–6678CrossRef

56.

Kelly RJ, Ernst LK, Larsen RD, Bryant JG, Robinson JS, Lowe JB (1994) Molecular basis for H blood group deficiency in Bombay (oh) and Para-Bombay individuals. Proc Natl Acad Sci U S A 91:5843–5847CrossRef

57.

Hooper LV, Gordon JI (2001) Glycans as legislators of host-microbial interactions: spanning the spectrum from symbiosis to pathogenicity. Glycobiol 11:1R–10R. https://doi.org/10.1093/glycob/11.2.1R CrossRef

58.

Tonetti M, Sturla L, Bisso A, Benatti U, De Flora A (1996) Synthesis of GDP-L fucose by the human FX protein. J Biol Chem 271(44):27274–27279CrossRef

59.

Lowe JB (1997) Selectin ligands, leukocyte trafficking, and fucosyltransferase genes. Kidney Int 51(5):1418–1426CrossRef

60.

Wang Y, Shao L, Shi S, Harris RJ, Spellman MW, Stanley P, Haltiwanger RS (2001) Modification of epidermal growth factor-like repeats with O-fucose. Molecular cloning and expression of a novel GDP-fucose protein O-fucosyltransferase. J Biol Chem 276(43):40338–40345CrossRef

61.

Feng X, Zhao L, Gao S, Song X, Dong W, Zhao Y, Zhou H, Cheng L, Miao X, Jia L (2016) Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4. Gene 578(2):232–241. https://doi.org/10.1016/j.gene.2015.12.028 CrossRefPubMed

62.

Carrascal MA, Silva M, Ramalho JS, Pen C, Martins M, Pascoal C, Amaral C, Serrano I, Oliveira MJ, Sackstein R, Videira PA (2017) Inhibition of fucosylation in human invasive ductal carcinoma reduces E-selectin ligand expression, cell proliferation and ERK1/2 and p38 MAPK activation. Mol Oncol 2(5):579–593. https://doi.org/10.1002/1878-0261.12163 CrossRef

63.

Zhou Y, Fukuda T, Hang Q, Hou S, Isaji T, Kameyama A, Gu J (2017) Inhibition of fucosylation by 2-fluorofucose suppresses human liver cancer HepG2 cell proliferation and migration as well as tumor formation. Sci Rep 7(1):11563. https://doi.org/10.1038/s41598-017-11911-9 CrossRefPubMedPubMedCentral

64.

Ohata S, Kinoshita S, Aoki R, Tanaka H, Wada H, Tsuruoka-Kinoshita S, Tsuboi T, Watabe S, Okamoto H (2009) Neuroepithelial cells require fucosylated glycans to guide the migration of vagus motor neuron progenitors in the developing zebrafish hindbrain. Development 136(10):1653–1663. https://doi.org/10.1242/dev.033290 CrossRefPubMed

65.

Moriwaki K, Narisada M, Imai T, Shinzaki S, Miyoshi E (2010) The effect of epigenetic regulation of fucosylation on TRAIL-induced apoptosis. Glycoconj J 27(7–9):649–659. https://doi.org/10.1007/s10719-010-9310-5 CrossRefPubMed

66.

Blanas A, Sahasrabudhe NM, Rodríguez E, van Kooyk Y, van Vliet SJ (2018) Fucosylated antigens in Cancer: an Alliance toward tumor progression, metastasis, and resistance to chemotherapy. Front Oncol 23(8):39. https://doi.org/10.3389/fonc.2018.00039 CrossRef

67.

Lv X, Song J, Xue K, Li Z, Li M, Zahid D, Cao H, Wang L, Song W, Ma T, Gu J, Li W (2019) Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake. Mol Carcinog 58:1–14. https://doi.org/10.1002/mc.22971 CrossRef

68.

Anugraham M, Jacob F, Nixdorf S, Everest-Dass AV, Heinzelmann-Schwarz V, Packer NH (2014) Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status. Mol Cell Proteomics 13(9):2213–2232. https://doi.org/10.1074/mcp.M113.037085 CrossRefPubMedPubMedCentral

69.

Medzihradszky KF, Kaasik K, Chalkley RJ (2010) Tissue-specific glycosylation at the Glycopeptide level. Mol Cell Proteomics 14(8):2103–2110. https://doi.org/10.1074/mcp.M115.050393 CrossRef

70.

Aoyagi Y, Isemura M, Yosizawa Z, Suzuki Y, Sekine C, Ono T, Ichida F (1985) Fucosylation of serum alpha fetoprotein in patients with primary hepatocellular carcinoma. Biochim Biophys Acta 830(3):217–223CrossRef

71.

Noda K, Miyoshi E, Kitada T, Nakahara S, Gao CX, Honke K, Shiratori Y, Moriwaki H, Sasaki Y, Kasahara A, Hori M, Hayashi N, Taniguchi N (2002) The enzymatic basis for the conversion of non-fucosylated to fucosylated alpha-fetoprotein by acyclic retinoid treatment in human hepatoma cells: activation of alpha 1,6 fucosyltransferase. Tumor Biol 23(4):202–211CrossRef

72.

Yan LM, Lin B, Zhu LC, Hao YY, Qi Y, Wang CZ, Gao S, Liu SC, Zhang SL, Iwamori M (2010) Enhancement of the adhesive and spreading potentials of ovarian carcinoma rmg-1 cells due to increased expression of integrin alpha5beta1 with the Lewis y-structure on transfection of the alpha1,2-fucosyltransferase gene. Biochim 92(7):852–857. https://doi.org/10.1016/j.biochi.2010.02.012 CrossRef

73.

Gao L, Yan L, Lin B, Gao J, Liang X, Wang Y, Liu J, Zhang S, Iwamori M (2011) Enhancive effects of Lewis y antigen on cd44-mediated adhesion and spreading of human ovarian cancer cell line rmg-i. J Exp Clin Cancer Res 30:15. https://doi.org/10.1186/1756-9966-30-15 CrossRefPubMedPubMedCentral

74.

Wang X, Gu J, Ihara H, Miyoshi E, Honke K, Taniguchi N (2006) Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem 281(5):2572–2577CrossRef

75.

Orczyk-Pawilowicz M (2007) The role of fucosylation of glycoconjugates in health and disease. Postepy Hig Med Dosw (Online) 61:240–252

76.

Mehta A, Comunale MA, Rawat S, Casciano JC, Lamontagne J, Herrera H, Ramanathan A, Betesh L, Wang M, Norton P, Steel LF, Bouchard MJ (2016) Intrinsic hepatocyte dedifferentiation is accompanied by upregulation of mesenchymal markers, protein sialylation and core alpha 1,6 linked fucosylation. Sci Rep 6:27965. https://doi.org/10.1038/srep27965 CrossRefPubMedPubMedCentral

77.

Wang H, Deng L, Cai M, Zhuang H, Zhu L, Hao Y, Gao J, Liu J, Li X, Lin B (2016) Annexin A4 fucosylation enhances its interaction with the NF-kB p50 and promotes tumor progression of ovarian clear cell carcinoma. Oncotarget 8(64):108093–108107. https://doi.org/10.18632/oncotarget.10226 CrossRefPubMedPubMedCentral

78.

Mitra I, Alley WR Jr, Goetz JA, Vasseur JA, Novotny MV, Jacobson SC (2013) Comparative profiling of N-glycans isolated from serum samples of ovarian cancer patients and analyzed by microchip electrophoresis. Proteome Res 12(10):4490–4496. https://doi.org/10.1021/pr400549e CrossRef

79.

Wang Y, Fukuda T, Isaji T, Lu J, Im S, Hang Q, Gu W, Hou S, Ohtsubo K, Gu J (2015) Loss of α1,6-fucosyltransferase inhibits chemical-induced hepatocellular carcinoma and tumorigenesis by down-regulating several cell signaling pathways. FASEB J 29(8):3217–3227. https://doi.org/10.1096/fj.15-270710 CrossRefPubMed

80.

Phillips T (2008) Regulation of transcription and gene expression in eukaryotes. Nature Education 1(1):199

81.

Prendergast JM, Galvao da Silva AP, Eavarone DA, Ghaderi D, Zhang M, Brady D, Wicks J, DeSander J, Behrens J, Rueda BR (2017) Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity. MAbs 9(4):615–627. https://doi.org/10.1080/19420862.2017.1290752 CrossRefPubMedPubMedCentral

82.

Bassoy EY, Kasahara A, Chiusolo V, Jacquemin G, Boydell E, Zamorano S, Riccadonna C, Pellegatta S, Hulo N, Dutoit V, Derouazi M, Dietrich PY, Walker PR, Martinvalet D (2017) ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells. EMBO 36(11):1493–1512. https://doi.org/10.15252/embj.201695429 CrossRef

83.

Sato Y, Isaji T, Tajiri M, Yoshida-Yamamoto S, Yoshinaka T, Somehara T, Fukuda T, Wada Y, Gu J (2009) An N-glycosylation site on the β-propeller domain of the integrin α5 subunit plays key roles in both its function and site-specific modification by β1, 4-N-acetylglucosaminyltransferase III. J Biol Chem 284(18):11873–11881. https://doi.org/10.1074/jbc.M807660200 CrossRefPubMedPubMedCentral

84.

Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human fc gamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277(30):26733–26740CrossRef

85.

Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278(5):3466–3473CrossRef

Titel: Ascites from Ovarian Cancer Induces Novel Fucosylated Proteins
verfasst von: Dulce Rosario Alberto-Aguilar
Verónica Ivonne Hernández-Ramírez
Juan Carlos Osorio-Trujillo
Dolores Gallardo-Rincón
Alfredo Toledo-Leyva
Patricia Talamás-Rohana
Publikationsdatum: 02.07.2019
Verlag: Springer Netherlands
Erschienen in: Cancer Microenvironment / Ausgabe 2-3/2019
Print ISSN: 1875-2292
Elektronische ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-019-00227-z

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Ascites from Ovarian Cancer Induces Novel Fucosylated Proteins

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2-3/2019

Immunosuppressive Tumor Microenvironment Status and Histological Grading of Endometrial Carcinoma

Cross-Talk Between circRNAs and mRNAs Modulates MiRNA-mediated Circuits and Affects Melanoma Plasticity

The Concomitant Expression of Human Endogenous Retroviruses and Embryonic Genes in Cancer Cells under Microenvironmental Changes is a Potential Target for Antiretroviral Drugs

Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment

Kinins in Glioblastoma Microenvironment

Pleiotropic Effects of Epithelial Mesenchymal Crosstalk on Head and Neck Cancer: EMT and beyond

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie